Loss of Rb1 Associated With the Onset of Acquired Resistance to Trastuzumab Deruxtecan in TP53-/HER2-Mutated Non-Small-Cell Lung Cancer: Case Series

被引：1
|
作者：
Gupta, Ashish [1 ,4 ]
Jatwani, Karan [1 ]
Gupta, Kush [2 ]
Qiu, Jingxin [3 ]
Dy, Grace K. [1 ]
机构：
[1] Roswell Park Comprehens Canc Ctr, Dept Med, Elm & Carlton St, Buffalo, NY USA
[2] Univ Massachusetts, Dept Med, Med Sch Baystate, Springfield, MA USA
[3] Roswell Park Comprehens Canc Ctr, Dept Pathol, Buffalo, NY USA
[4] Roswell Park Comprehens Canc Ctr, Dept Med, Elm & Carlton St, Buffalo, NY 14203 USA
来源：
JCO PRECISION ONCOLOGY | 2023年 / 7卷
关键词：
D O I：
10.1200/PO.22.00476
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：5
相关论文
共 50 条
  • [41] PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer
    Riki Okita
    Ai Maeda
    Katsuhiko Shimizu
    Yuji Nojima
    Shinsuke Saisho
    Masao Nakata
    Cancer Immunology, Immunotherapy, 2017, 66 : 865 - 876
  • [42] PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer
    Okita, Riki
    Maeda, Ai
    Shimizu, Katsuhiko
    Nojima, Yuji
    Saisho, Shinsuke
    Nakata, Masao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (07) : 865 - 876
  • [43] Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02
    Qi, Zhenhao
    Tokuhiro, Shinya
    Odegaard, Justin I.
    Wienke, Sara
    Karnoub, Maha
    Feng, Wenqin
    Shiga, Ryota
    Smit, Egbert F.
    Goto, Yasushi
    De Langen, Adrianus J.
    Goto, Koichi
    Pereira, Kaline
    Khambata-Ford, Shirin
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2025, 27 (02) : 119 - 129
  • [44] Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series
    Bernstein, Ezra
    Luo, Jia
    Wang, Kaiwen
    Negrao, Marcelo V.
    Janne, Pasi A.
    Sabari, Joshua K.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [45] Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy
    Tsui, David Chun Cheong
    Aisner, Dara
    Nijmeh, Hala
    Bao, Liming
    Menter, Alexander
    Camidge, D. Ross
    CLINICAL LUNG CANCER, 2022, 23 (02) : E99 - E103
  • [46] Ceritinib/crizotinibLiver injury, vision disorder and development of crizotinib resistance in ROS1-rearranged non-small-cell lung cancer: 2 case reports
    Reactions Weekly, 2023, 1974 (1) : 102 - 102
  • [47] Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment
    Giustini, Nicholas P.
    Patel, Sandip Pravin
    Myall, Nathaniel J.
    Moura, Jose Fernando do Prado
    Kulkarni, Amit
    Chao, Richard C.
    Wakelee, Heather
    Bazhenova, Lyudmila
    JCO PRECISION ONCOLOGY, 2022, 6
  • [48] Circ-MAN1A2 Contributes to the Acquired Resistance of Gefitinib by Binding to miR-409-3p to Induce TWIST1 Expression in Non-small-cell Lung Cancer
    Li, Yun
    Liu, Jinping
    Luo, Rong
    You, Yong
    Chen, Guiming
    BIOTECHNOLOGY AND BIOPROCESS ENGINEERING, 2022, 27 (04) : 556 - 571
  • [49] Circ-MAN1A2 Contributes to the Acquired Resistance of Gefitinib by Binding to miR-409-3p to Induce TWIST1 Expression in Non-small-cell Lung Cancer
    Yun Li
    Jinping Liu
    Rong Luo
    Yong You
    Guiming Chen
    Biotechnology and Bioprocess Engineering, 2022, 27 : 556 - 571
  • [50] Analytical and clinical validation of oncomine Dx target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non-small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL01/02)
    Li, Bob T.
    De langen, Adrianus
    Goto, Koichi
    Vitazka, Patrik
    Qi, Zhenhao
    Ha, Thomas
    Marie, Anne
    Roth, Velasco
    Karnoub, Maha
    Feng, Wenqin
    Pereira, Kaline
    Shiga, Ryota
    Khambata-Ford, Shirin
    Goto, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345